Menu
Back to Archived Journals » Oncolytic Virotherapy » Volume 6
Editorial announcing PubMed indexing of Oncolytic Virotherapy
Authors Farassati F
Received 25 November 2016
Accepted for publication 25 November 2016
Published 15 February 2017 Volume 2017:6 Pages 19—20
DOI https://doi.org/10.2147/OV.S128720
Checked for plagiarism Yes
Faris Farassati1,2
1Saint Luke’s Cancer Institute-Saint Luke’s Marion Bloch Neuroscience Institute, Kansas City, MO, USA; 2Midwest Biomedical Research Foundation, Kansas City, MO, USA
I am delighted to announce that Oncolytic Virotherapy has been accepted for indexing with PubMed. This is an exciting first step in the life of a new life sciences journal, when the scientific quality of its articles is proven high enough to meet the National Library of Medicine’s standards for archiving. All articles published in Oncolytic Virotherapy are available through PubMed Central (as well as Dove Medical Press) and are now discoverable through National Center for Biotechnology Information (NCBI) suite of databases, meaning increased exposure for our authors and their research.
The field of oncolytic virotherapy has moved rapidly since the 1990s when the advent of genetic engineering renewed interest in the adaptation of viruses for cancer gene therapy.1 Publications in this field reached an all-time high in 2012,2 the same year that Oncolytic Virotherapy was launched. The journal has published high-quality reviews, case reports, and original research articles across a wide range of topics. Our most viewed article is currently “Oncolytic viral therapy for pancreatic cancer: current research and future directions”,3 while the review “Oncolytic viral therapy: targeting cancer stem cells”4 has generated the most citations.
Disclosure
The author reports no conflicts of interest in this work.
References
Sokolowski NAS, Rizos H, Diefenbach RJ. Oncolytic virotherapy using herpes simplex virus: how far have we come? Oncolytic Virother. 2015;4:207–219. | ||
Scopus. Scopus Search Results Analysis for ‘Oncolytic Virotherapy’. Amsterdam: Elsevier B.V. Available from: https://www.scopus.com/term/analyzer.uri?sid=8E36C008BD39BCC8AEAA7C499A7D3108.wsnAw8kcdt7IPYLO0V48gA%3a10&origin=resultslist&src=s&s=TITLE-ABS-KEY%28oncolytic+virotherapy%29&sort=plf-f&sdt=b&sot=b&sl=36&count=2947&analyzeResults=Analyze+results&txGid=8E36. Accessed October 31, 2016. | ||
Ady JW, Heffner J, Klein E, Fong Y. Oncolytic viral therapy for pancreatic cancer: current research and future directions. Oncolytic Virother. 2014;3:35–46. | ||
Smith TT, Roth JC, Friedman GK, Gillespie GY. Oncolytic viral therapy: targeting cancer stem cells. Oncolytic Virother. 2014;3:21–33. | ||
Dove Medical Press encourages responsible, free and frank academic debate. The content of the Oncolytic Virotherapy ‘Editorial’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Oncolytic Virotherapy editors. While all reasonable steps have been taken to confirm the content of each Editorial, Dove Medical Press accepts no liability in respect of the content of any Editorial, nor is it responsible for the content and accuracy of any Editorial. |
© 2017 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.